PCAC · Voted Friday, July 24, 2026
Epitalon at the compounding committee: recommended
On July 24, 2026, the committee voted to recommend adding Epitalon — both the free base and the acetate — to the 503A Bulks List: seven members in favour, one abstaining, and four or five against, depending on the report. FDA staff had proposed adding neither form. As of September 25, 2026, FDA has not acted on the recommendation.
FDA staff's position, June 29: FDA proposes not adding either epitalon substance to the 503A Bulks List, citing inadequate characterisation, limited historical use, no evidence of effectiveness for insomnia, and an absence of safety data — including on whether it would cause harm in humans.
Published July 16, 2026 · Updated September 25, 2026 · By the Grey Peptides Editorial Board · ✓ Sourced from FDA's briefing document
FDA staff had proposed adding neither form of Epitalon; the committee disagreed. What that changes today: nothing yet. As of September 25, 2026, FDA has not added Epitalon to the 503A Bulks List or placed it in Category 1, so compounding it still falls outside the 503A exemption.
Published reports agree on every tally except epitalon's. Hyman, Phelps & McNamara's FDA Law Blog and McDermott report 7–4; RAPS reports 7–5; all three give one abstention. FDA has not posted minutes, and we will record the official count when it does. The outcome is not in dispute.
| Substances | Epitalon (free base) and epitalon acetate |
| Also known as | Epithalon, AEDG, Ala-Glu-Asp-Gly |
| Length | 4 amino acids (Ala-Glu-Asp-Gly) |
| Use FDA reviewed | Insomnia |
| Forms proposed | Subcutaneous injection, per the nomination package |
| Nomination | Nominations withdrawn; FDA evaluated at its own discretion |
| FDA staff position | Proposed not adding either form to the 503A Bulks List |
| Committee vote | Recommended — 7–4 or 7–5, 1 abstention (July 24, 2026) |
What FDA reviewed it for
FDA evaluated epitalon for insomnia — not for the anti-ageing uses it is mostly marketed for.
This is not a detail to skip past. FDA evaluates a bulk drug substance in the context of the use proposed for it — so the question in front of the committee was not "is Epitalon useful?" but "does the evidence support compounding Epitalon for insomnia?" A substance can have an interesting research literature in a completely different area and still fail this test, because that literature was never the thing under review.
FDA's specific objections
FDA weighs four criteria: whether the substance is well characterised physically and chemically, whether it has been used historically in compounding, what evidence exists on effectiveness, and what safety issues its use in compounding raises. Here is where Epitalon landed on each.
FDA says neither form is well characterised, citing naming that does not follow established chemical nomenclature standards among other gaps.
FDA describes the information on historical use as limited — weaker than for most of the other six.
FDA concluded there is a lack of evidence to support effectiveness for insomnia, a condition it notes is associated with multiple serious adverse health outcomes and for which approved drugs with well-characterised safety profiles exist.
FDA says it lacks data to support the safety of these substances in humans, including whether they would cause harm when given subcutaneously, and did not identify information addressing immunogenicity risk.
What is specific to Epitalon
Six of the seven objections above could be written about almost any of the compounds on the July agenda. These next points could not — they are what makes this file different from the other six.
FDA's briefing describes epitalon being marketed online by wellness clinics and concierge practices as an anti-ageing agent — with websites calling it a fountain of youth, claiming it raises telomerase and thereby reverses ageing, extends lifespan and prevents cancer, heart disease and dementia. FDA reports these as claims made by those websites. They are not findings, and FDA did not evaluate epitalon for any of them.
FDA describes three studies of epitalon's effect on spontaneous malignant tumour incidence and lifespan in mice — similar designs, all from the same research group. It identified no additional studies assessing genotoxic potential, and no developmental or reproductive toxicity studies. For a compound promoted for indefinite anti-ageing use, the long-term data is three related mouse studies from one lab.
FDA notes an orphan drug designation for retinitis pigmentosa granted in September 2010 was withdrawn or revoked in January 2016. A designation is not an approval, and this one no longer stands.
The evidence picture
Grey Peptides grades epitalon's evidence base as low. The literature is largely Russian-language work centred on one research group, and the marketed anti-ageing claims are not supported by the kind of evidence a regulator weighs. Note that FDA spells it “epitalon”; this site's encyclopedia entry uses “Epithalon,” and both refer to the same tetrapeptide.
Two readings of the same file are worth separating. FDA's conclusion is about a regulatory question — whether the record supports letting pharmacists compound this substance for this use. That is a higher bar than "there is some interesting science here," and a lower bar than "this substance is harmful." Almost everything FDA said about Epitalon is a statement about missing information, not a finding of harm. Reporting that as "FDA says Epitalon is dangerous" is wrong. So is reporting it as "FDA found no safety problems."
Where this sits in our encyclopedia
Our entry on this compound covers the underlying pharmacology, the published literature, and the status picture independent of this meeting. The two are separate reads: the encyclopedia entry is about the compound, and this page is about the regulatory file.
Mechanism, evidence grade, half-life, approval status, and sources. PCAC July 2026 — the full picture
All seven compounds, what the vote does and doesn't change, and what to watch. Peptide Regulatory Status Tracker
Category 1/2/3, 503A vs 503B, and where every peptide sits.
The other six compounds
BPC-157 · KPV · TB-500 · MOTS-c · Emideltide (DSIP) · Semax
FDA — July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee ↗
FDA briefing documents released June 29, 2026. Federal Register notice 91 FR 20465, published April 16, 2026 (FR Doc. 2026-07361), Docket No. FDA-2025-N-6895. FDA Briefing Document for Epitalon (free base) and epitalon acetate, released June 29, 2026.
- FDA — July 23–24, 2026 PCAC meeting page: briefing documents, roster, presentations, video (last updated Aug 6, 2026)
- FDA — Questions put to the committee (separate free-base and acetate votes)
- FDA — Bulk drug substances nominated under 503A, by category (updated May 14, 2026; read Sept 25, 2026)
- FDA — Next PCAC meeting, before the end of February 2027 (no date set)
- Hyman, Phelps & McNamara, FDA Law Blog — July 24 votes
- McDermott — PCAC backs majority of peptides in two-day public meeting
- RAPS Regulatory Focus — committee backs two more peptides, rejects one (July 24, 2026)
- Fierce Pharma — first-day votes (July 23, 2026)
- Frier Levitt — what the recommendations mean (Sept 17, 2026)
FDA had not posted minutes as of September 25, 2026, so tallies are as reported by the sources above. Published reports agree on every tally except epitalon's. Hyman, Phelps & McNamara's FDA Law Blog and McDermott report 7–4; RAPS reports 7–5; all three give one abstention. FDA has not posted minutes, and we will record the official count when it does. The outcome is not in dispute.